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Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic small vessel vasculitis associated with
asthma and eosinophilia. Optimal therapy for maintenance of remission is yet to be deﬁned. We present
a case-series of three patients with EGPA in whom IFN-a, an immunomodulatory cytokine induced
remission, which was maintained even after discontinuation of the drug. In all patients (ages 60, 51, and
50 years), remission was associated with normalisation of eosinophil counts and IgE-levels. Moreover,
the patients remained in remission for one to four years. Two patients did not need further immuno-
suppression, one patient required low dose maintenance therapy.
Although reversible side effects occur, IFN-a-therapy induces long-term remission of EGPA even after
discontinuation of treatment.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
EGPA is a rare systemic necrotizing vasculitis of the small-
vessels, ﬁrst described as allergic granulomatosis and angiitis in
1951 [1]. It is characterized by bronchial asthma with pulmonary
inﬁltrates, peripheral eosinophilia and involvement of various or-
gans such as heart, peripheral nerves, kidneys and the gastroin-
testinal tract. EGPA has been categorized as antineutrophil
cytoplasmatic antibodies-associated-vasculitis, however only 30e
40% of the patients are ANCA positive [2,3].
There exist several treatment options for induction of remission,
but relapses are frequent and the most effective and safest therapy
for maintenance of remission is yet to be deﬁned.
IFN-a-therapy inhibits eosinophil degranulation and potentially
reverses TH2-mediated immune responses [4]. Several case series
indicate its efﬁcacy [5e7] in treating EGPA and a recent prospective
clinical trial [8,9] demonstrated that IFN induces remission. Here,is with polyangiitis; IFN-a,
atic antibodies; PNP, poly-
ion Units; DMARDs, disease
, Friedrich-Schiller-University
any.
Seeliger).
r Ltd. Open access under CC BY license.we report the course of three ANCA-negative patients [Table 1]
with severe EGPA treated with IFN-a for up to 131 months.
2. Case reports
2.1. Case 1
A 60-year-old female non-smoker presented with progressive
dyspnoea and airway obstruction in 1999. Past medical history
included allergic diathesis, chronic sinusitis and refractory tachy-
cardia. The patient repeatedly received i.v. corticosteroids. Poly-
neuropathy (PNP) of both legs occurred one year before admission.
X-rays of the chest over the past two years showed migrating in-
ﬁltrates. Past lab-exams revealed peripheral eosinophilia of 38%.
ANCA antibodies could not be detected. Bronchoscopy and bron-
choalveolar lavage (BAL) showed signiﬁcant eosinophilia of 61.5%.
Transbronchial mucosal biopsies revealed eosinophil inﬁltrations
and eosinophil vasculitis. Thus, the patient met all six ACR diag-
nostic criteria for EGPA.
At ﬁrst presentation, the patient scored a BVAS of 21. Treatment
with IFN-a2b (9 Million Units (MU) per week) was initiated. Under
therapy, the patient showed remarkable clinical improvement and
remission was induced after 6 months (BVAS ¼ 0). The area of
sensoric neurologic deﬁcit of the leg regressed 20 cm distally
following 24 months of treatment. Her initial blood eosinophil
count decreased rapidly [Table 2]. Except for discrete hyperinﬂa-
tion, pulmonary function tests normalized after 12 months of
treatment.
Table 1
Characteristics of 3 ANCA-neg. patients with EGPA treated with IFN-a (Part 1).
Pat. Age, sex FFS ANCA DEI Disease duration
[months]a
Previous
treatment
PRD [mg/d] Histologyb Clinical features
1 60, f 0 Neg. 6 36 PRD Irr. 100 mg pulses L Arrhythmia, eosinophilic alveolitits,
mononeuritis multiplex
2 61, m 0 Neg. 6 61 PRD, iv.CYC 0c e Mononeuritis multiplex, eosinophilic alveolitis
3 50, f 0 Neg. 4 120 PRD 100 e Eosinophilic alveolitis
FFS: Five-factor score, DEI: disease extent index, PRD: prednisolon, i.v.CYC: intraveneous cyclophosphamide, L: lung.
a Prior to IFN-a-treatment.
b Biopsy proven vasculitis.
c PRD-dosage was tapered and discontinued two weeks prior to treatment from 70 mg/d.
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relapse following 26months of therapy (BVAS¼ 6) [Table 2].Within
a total of 131 months of IFN-therapy, IFN dosages and preparation
was adjusted as shown in Fig.1. Nine years after initiation of therapy,
PNP progressed. As asthma and sinusitis remained clinically stable
and peripheral eosinophil count was at 53 109/l (1%), IFN-induced
neuropathy was suspected, which remained after switching treat-
ment to PEG-IFN-a. Therefore, IFN-a was discontinued, which was
followed by clinical improvement of neuropathy. After 12 months
PNP had not progressed, and serum IgE-level fell to 55.1 IU/ml with
an eosinophil count of 170  109/l (2%) and no ENT or asthma-
symptoms. The patient remained in complete remission for 12
months without IFN or systemic prednisolone [Table 3].
2.2. Case 2
A 60-year-old male non-smoker presented in 2003 with a history
of asthma,chronic sinusitiswithanosmiaandmononeuritismultiplex
of both hands and feet as well as atrophy of the left forearmmuscles.
Laboratory exams revealed a peripheral blood eosinophil count of
650  109/l (10%) and a serum IgE-level of 599 IU/ml. Bronchoscopy
and BAL showed signiﬁcant eosinophilia of 15%. Meeting four of six
ACR diagnostic criteria, the patient was diagnosed with EGPA.
The patient received oral corticosteroids for 7 months and
subsequently 11 pulses of cyclophosphamide over a period of 17
months. However symptoms relapsed and IFN-treatment was
initiated [Table 2].
Following two months of IFN-therapy, the patient reported com-
plete regression of dyspnoea and anosmia with improved lung-
function tests, which was followed by no further progression of PNP.
After 6 months, complete remission was induced (BVAS ¼ 0). Side
effects including arthralgia and muscle pain after IFN-injection were
transitory.
Following 55 months of treatment, IFN-therapy was dis-
continued due to development of an ANAþ and SMAþ autoimmune
hepatitis. Prednisolone therapy (25 mg/d) was initiated, leading to
normalization of liver enzymes. Prednisolone was tapered to 5 mg
as a maintenance therapy within three months. After discontinu-
ation, asthmatic complaints recurred.
2.3. Case 3
A 50-year-old female non-smoker presented with dyspnoea,
sinusitis and airway obstruction. The patient had a history ofTable 2
Characteristics of 3 ANCA-neg. patients with EGPA treated with IFN-a (Part 2).
Pat. Before therapy Remission
Eos [109/l] IgE [IU/ml] FEV1 [l] Eos [109/l] IgE
1 896 (14%) 859 2.23 (83%) 45 (1%) e
2 720 (10%) 509 2.57 (79%) 84 (3%) 117
3 1080 (12%) 190 1.27 (45%) 430 (10%) 19asthma and polyvalent allergy followed by chronic sinusitis. Eight
years prior to admission, symptomatic prednisolone therapy (10e
100 mg/d) was initiated due to severe dyspnoea.
On admission, the laboratory exams and pulmonary function
tests showed an elevated peripheral eosinophil count and a severe
airway obstruction [Table 2]. BAL revealed a signiﬁcant bron-
choalveolar eosinophilia. An X-ray of the chest showed pulmonary
inﬁltrates. At the time of presentation, the patient scored a BVAS of
8 and the diagnosis of EGPA was established.
In order to induce remission, 9 MU of IFN-a2b per week were
administered. Under therapy, the patient showed signiﬁcant clin-
ical improvement. Within two months of IFN-a, the prednisolone
dosage could be decreased to 4 mg/d. Side effects are listed in
Table 2. The peripheral eosinophil count dropped to 415109/l (5%)
after two months and was at 69  109/l (1%) after ﬁve months of
therapy. Additionally, the FEV1 improved from 1.27 L (44%) to 2.17 L
(77%) after two months of IFN-a therapy.
Following six months of therapy, prednisolone could be dis-
continued. A subsequent respiratory infection resulted in a
temporary re-administration of prednisolone, which could be
tapered and discontinued three months later. At that time, after
16 months of treatment complete remission was induced
(BVAS ¼ 0). Following twenty months of therapy, the patient
suffered a relapse (BVAS ¼ 11) and presented with worsening of
PNP and elevated peripheral eosinophil count [Table 2]. IFN-a-
dosage was increased, combined with prednisolone starting with
40 mg/d. IFN-a was switched to Peg-IFN-a due to enduring fa-
tigue and complete remission was achieved. Following two
months of Peg-IFN-a, the peripheral eosinophil count dropped to
0% and the serum IgE-level decreased from 93.7 IU/l to 43.8 IU/l
one year after administration of Peg-IFN-a. Prednisolone was
tapered and could be discontinued 18 months after relapse
without recurrence of symptoms.
After ﬁve years, IFN-a-therapy was discontinued due to slowly
progressive myelosuppression (erythrocyte count of 2.9/pl). Since
then the patient remained in remission without prednisolone.
3. Discussion
The conclusions of the case series presented herein are three-
fold. Firstly, the cases conﬁrm previous observations [5e8,10]
showing that IFN induces complete remission in patients with
EGPA. Secondly, the study extends previously published data and
demonstrates that remission is maintained under treatment for upRelapse
[IU/ml] FEV1 [l] Eos [109/l] IgE [IU/ml] FEV1 [l]
2.57 (103%) 118 (2%) 466 1.62 (61%)
0 2.72 (85%) e e e
4 2.57 (92%) 1386 (21%) e 2.32 (83%)
Table 3
Outcome of 3 patients treated for remission and maintenance with IFN-a.
Pat. IFN-therapy
[Months]
Follow-up
[Months]
Side effects
[Management]
Relapses (Month)
[Management]
Outcome
1 131 144 Progress of PNP
[discontinuation of IFN-a]
Asthma exacerbation
(26) [IFN-a[]
IFN-a discontinued (remission without
immunosuppresive agents)
2 55 67 Autoimmune hepatitis
[discontinuation of IFN-a]
None IFN-a discontinued, recurrence of asthma
3 61 109 Hyperthyreosis, anaemia
[discontinuation of IFN-a]
Mononeuritis multiplex (20)
[IFN-a[, PRD[]
IFN-a discontinued (remission without
immunosuppresive agents)
[ ¼ increase in the dosage, Y ¼ decrease in the dosage.
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that remission is maintained up to four years after IFN therapy has
been discontinued. Because IFN inhibits the Th2 immune pattern
[11], the data suggest that the cytokine shows a long-lasting
immunomodulatory action in EGPA, which persist even after
treatment has been terminated.12%
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goal. Corticosteroids alone or in combination with immunosup-
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lapses are likely with low dosages or discontinuation. In addition,
both spontaneous remission and treatment-induced long-term
maintenance of remission are uncommon.
With the introduction of disease-modifying drugs and biologics,
which, in contrast to standard immunosuppressive drugs, selec-
tively intercept one speciﬁc disease pathway, remission has become
a realistic treatment goal. For instance, in rheumatoid arthritis (RA),
another autoimmune disease, blocking the activity of tumour ne-
crosis factor (TNF) using anti-TNF-antibodies over a period of four
years leads to remission of RA in 43% [12] and in 13% of these pa-
tients drug therapy can even be discontinued for a prolonged
period [13]. The observations made in RA may have interesting
parallels with EGPA. Both RA and EGPA are autoimmune disorders
and both are treated with standard immunosuppressive treatment
including corticosteroids and immunosuppressants. In both dis-
eases spontaneous and treatment-induced remission using stan-
dard immunosuppression regimens are uncommon. Hence, in
contrast to standard treatment, the case series presented herein
suggest that immunomodulatory treatment of EGPA with IFN in-
duces remission that may continue for several years. In fact,
immunomodulatory therapy may be superior to standard immu-
nosuppression as it may induce long-term remission even after
discontinuation of treatment.
Little is known regarding maintenance of remission in EGPA
treated with IFN. A small study with 13 patients reported a mean
time to ﬁrst relapse of 17 months [9]. In RA, almost half of the
patients in whom maintained remission was achieved after
discontinuation of therapy with DMARDs experienced a relapse
during a 15-year follow-up period [14]. Thus, we cannot exclude
that some, if not all, patients with EGPA in remission presented
herein may also develop a relapse in the future.
In RA, a proportion of patients with apparent clinical remission
showed signs of progressive joint damage indicating subclinical
disease activity [15]. This may be similar to the cases presented
above, which showed an increase in IgE serum levels and periph-
eral eosinophil counts whilst still being in clinical remission. In
addition, there was no indication for organ involvement including
heart and lung. However, whether these biological parameters
precede a relapse in EGPA remains unclear.
IFN-treatment may cause signiﬁcant adverse effects. All three
patients experienced early side effects like arthralgia, myalgia and
malaise and patient 3 also experienced depression after IFN-
injections, but those side effects were transient. Patient 3 also
developed hyperthyroidism, but was euthyroid under methima-
zole. Eventually, all patients had to discontinue IFN due to adverse
events that disappeared shortly after discontinuation of treatment
or did not progress further (PNP of patient 1).
Recent studies have shown that rituximab, a B-cell-depleting
anti-CD20 monoclonal antibody and mepolizumab, an anti-IL-5-
antibody also induce remission in EGPA [16e18]. However, data
on long-term efﬁcacy in maintaining remission after discontinua-
tion of treatment are not available making a reliable comparison of
IFN-a to rituximab or mepolizumab impossible.
We fully acknowledge the limitations of an observational study
in only three patients. For instance, the patients presented were
ANCA-negative. Thus, the beneﬁcial effect of IFN may not apply to
ANCA-positive cases. Previous reports [7,8] however have demon-
strated that ANCA-positive patients equally respond to IFN-a. We
also are aware that IFN may cause side effects. However, these
adverse reactions were reversible. In addition, we believe that thisstudy provides important preliminary evidence that IFN may be
effective in inducing and maintaining remission in severe EGPA
making it superior to standard immunosuppression which is often
limited by poor efﬁcacy or toxicity. Obviously, randomized, double-
blind and controlled trials need to be conducted to assess whether
IFN is preferable in achieving long-term maintenance of remission
in patients with severe EGPA.
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